Anzeige
Mehr »
Login
Mittwoch, 28.07.2021 Börsentäglich über 12.000 News von 669 internationalen Medien
Countdown: Die derzeit größte Kurswette mit Ansage!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PN6W ISIN: US4268971045 Ticker-Symbol: 336P 
Tradegate
28.07.21
15:30 Uhr
1,332 Euro
+0,025
+1,91 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
HEPION PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
HEPION PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2971,32922:02
1,2641,37822:00

Aktuelle News zur HEPION PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders5
13.07.Hepion Pharmaceuticals, Inc. - 8-K, Current Report8
13.07.Hepion's NASH drug ready for phase 2b after clearing safety bar, dropping efficacy breadcrumbs10
HEPION PHARMACEUTICALS Aktie jetzt für 0€ handeln
13.07.Hepion shares fall after CRV431 mid-stage NASH study results5
25.06.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Adjournment of Annual Meeting5
09.06.Hepion Pharmaceuticals to join Russell Microcap12
09.06.Hepion Pharmaceuticals, Inc. - 8-K, Current Report6
09.06.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals to be Added to the Russell Microcap Index9
26.05.Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)7
14.05.Hepion Pharmaceuticals, Inc. - 10-Q, Quaterly Report5
06.05.Hepion Pharmaceuticals, Inc. - 8-K, Current Report3
06.05.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment ...6
29.04.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Presents Machine Learning "Learn and Confirm" Modeling Strategy at 4th Global NASH Congress6
07.04.Hepion Pharmaceuticals - Phase IIa readout upcoming305Despite a challenging operating environment due to COVID-19, Hepion was able to advance its CRV431 development program (for the treatment of non-alcoholic steatohepatitis, NASH) without major disruption...
► Artikel lesen
31.03.Hepion Pharmaceuticals, Inc. - 10-K, Annual Report6
23.03.Hepion Pharmaceutical's Lead Drug Shows Antifibrotic Effects In Animal Studies10
23.03.Hepion Pharmaceuticals, Inc. - 8-K, Current Report3
23.03.Hepion Pharmaceuticals, Inc.: DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical's ...3
22.03.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference3
18.03.ENDRA Life Sciences Inc.: ENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials1.901Hepion to include ENDRA's TAEUS? technology in Phase 2b trial of CRV431 ANN ARBOR, MI and EDISON, NJ / ACCESSWIRE / March 18, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic...
► Artikel lesen
Seite:  Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4